AtriCure Announces First Quarter 2025 Financial Results
AtriCure Reports Strong First Quarter 2025 Financial Results Driven by Product Innovation and Market Expansion AtriCure, Inc. (Nasdaq: ATRC), a global leader in developing innovative surgical solutions for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and…
Xencor Reports Positive Interim Results for XmAb942 in First Human Study
Xencor Reports Positive Interim Data From First-in-Human Study of XmAb942, Plans Phase 2b Trial for Inflammatory Bowel Disease Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company specializing in the development of engineered monoclonal antibodies and cytokines to treat cancer and…
QIAGEN Unveils New Lentivirus Tools to Advance Quality Control in Cell and Gene Therapy
QIAGEN Expands Digital PCR Portfolio With Advanced Lentivirus Solutions to Elevate Quality Control in Cell and Gene Therapy Manufacturing QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA), a global leader in sample and assay technologies for molecular diagnostics and life sciences,…
Sage Therapeutics Delivers Q1 2025 Results, Showcases Pipeline Progress and Strategic Developments
Sage Therapeutics Reports First Quarter 2025 Financial Results, Showcases Strong Momentum for ZURZUVAE and Pipeline Advancements Sage Therapeutics, Inc. (Nasdaq: SAGE) has announced its financial results for the first quarter ended March 31, 2025, highlighting solid progress in the commercialization…
DEFINE-HT Study Shows Prospera™ Heart Predicts Outcomes Better Than Biopsy
DEFINE-HT Clinical Trial Shows Prospera™ Heart Accurately Predicts Outcomes and Outperforms Biopsy in Heart Transplant Surveillance Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, has announced the results of its landmark DEFINE-HT clinical trial,…
Mirion Reports Q1 2025 Financial Results and Revises Full-Year Outlook
Mirion Reports Strong First Quarter 2025 Results and Updates Full-Year Guidance Amid Robust Market Demand Mirion Technologies, Inc. (“Mirion” or the “Company”) (NYSE: MIR), a leading provider of radiation detection, measurement, analysis, and monitoring technologies serving nuclear, medical, defense, and…
Guardant Health Showcases Shield Test’s Accuracy Across 10 Cancers
Guardant Health Unveils Compelling Data on Shield Multi-Cancer Detection Test at AACR 2025, Showcasing High Specificity and Sensitivity Across Ten Tumor Types Guardant Health, Inc. (Nasdaq: GH), a prominent leader in precision oncology, has released new clinical data demonstrating the…
Microba Achieves Breakthrough in IBD Research and Secures Major Gastroenterology Partnership
Microba Life Sciences Achieves Breakthrough in IBD Diagnostics and Forms Strategic Partnership with Leading Gastroenterology Provider Microba Life Sciences Limited (ASX: MAP), a precision microbiome company at the forefront of next-generation diagnostics, today announced two major milestones that reinforce its…
D3 Bio Showcases D3S-001 as Promising KRAS G12C Inhibitor in Nature Medicine and AACR 2025
D3 Bio Showcases Next-Generation KRAS G12C Inhibitor D3S-001 in Nature Medicine and AACR 2025 Presentation, Demonstrating Breakthrough Efficacy and Resistance Overcoming Potential D3 Bio, a clinical-stage biotechnology company at the forefront of precision oncology innovation, has announced a major milestone…
NIH’s Shift Toward Human-Based Research Hailed as Major Victory for Animal Welfare
NIH’s Commitment to Human-Based Research Applauded as a Major Milestone for Science and Animal Welfare The Physicians Committee for Responsible Medicine, a nonprofit organization committed to advancing ethical medical research and improving public health, is celebrating what it calls a…
Swisslog Healthcare Expands AutoPack Capabilities with New Complementary Features
Swisslog Healthcare Enhances AutoPack™ System with New Features to Boost Efficiency and Flexibility in Hospital Pharmacies Swisslog Healthcare, a global leader in pharmacy automation and transport solutions, has unveiled a suite of new features designed to further improve the capabilities…
InVitria Unveils Groundbreaking Optibumin® 25 for Closed-System Biomanufacturing Applications
InVitria Launches Optibumin® 25: A Groundbreaking 25% Recombinant Human Serum Albumin Designed for Closed-System Biomanufacturing InVitria, a recognized innovator in the development of recombinant, chemically defined components for biomanufacturing, has announced the commercial launch of Optibumin® 25 — a first-of-its-kind…